ArticleEuropean journal of neurology2025

Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.

Gabriel Bsteh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.